The value of new drugs depends on your perspective

Medications
September 16, 2011

Here is an interesting survey from Quintiles, the large clinical outsourcing company, on how different groups perceive the value of new drugs.

The first problem is that not everyone can agree on what’s valuable. Surveying managed-care people and physicians, the number one factor mentioned is cost. Biopharma respondents mentioned cost, but were more weighted toward outcomes (which, for example, was a factor in only 10% of the physician responses). Patients … …

Read more…

The value of new drugs depends on your perspective

Bias in top tier academic journals

Medications
June 23, 2011

Venture-capital guy Bruce Booth has a provocative post, based on experience, about how reproducible those papers are that make you say, “Someone should try to start a company around that stuff”:

The unspoken rule is that at least 50% of the studies published even in top tier academic journals – Science, Nature, Cell, PNAS, etc… – can’t be repeated with the same conclusions by an industrial lab. In particular, …

Read more…

Bias in top tier academic journals

Potassium iodide won’t protect you from nuclear reactor radioactive isotopes

Medications
April 6, 2011

Well, the nuclear crisis in Japan seems to be causing a run on potassium iodide (KI), and not just in Japan.

If news reports are to be believed, people in many other regions (such as the west coast of the US and Canada) are stocking up, and some of these people may have already started dosing themselves.

Don’t do that. Don’t …

Read more…

Potassium iodide won’t protect you from nuclear reactor radioactive isotopes